Relay Therapeutics will report Q4 and full-year 2025 financial results on February 26, 2026, focusing on cancer therapies.
Quiver AI Summary
Relay Therapeutics, Inc. announced that it will release its fourth quarter and full year 2025 financial results and corporate highlights on February 26, 2026, after the markets close. The company, which focuses on developing precision medicine therapies for cancer and genetic diseases, utilizes its innovative Dynamo® platform to address challenging protein targets. Its lead product, zovegalisib, is a novel PI3Kα inhibitor currently in a Phase 3 clinical trial for HR+/HER2- metastatic breast cancer, and it is also being explored for PI3Kα-driven vascular anomalies. Relay's development pipeline further includes treatments for NRAS-driven solid tumors and Fabry disease. For additional details, the company invites visits to its website or LinkedIn page.
Potential Positives
- Relay Therapeutics is set to report its fourth quarter and full year 2025 financial results, indicating transparency and regular communication with stakeholders.
- The company is advancing its lead clinical asset, zovegalisib, which is the first pan-mutant selective PI3Kα inhibitor in clinical development, showcasing innovation in cancer treatment.
- Relay's use of the Dynamo® platform highlights their commitment to integrating advanced technologies in drug development, potentially increasing the effectiveness of treatments for previously challenging conditions.
- The ongoing Phase 3 clinical trial of zovegalisib in HR+/HER2- metastatic breast cancer suggests significant progress in clinical development, which could lead to valuable outcomes for patients and the company’s growth.
Potential Negatives
- The press release did not provide specific financial performance details, which may raise concerns about transparency and financial health among investors.
- There is no mention of any recent positive developments or milestones achieved in the clinical trials, potentially indicating stagnation in progress.
- The lack of additional data or insights into the timeline for the Phase 3 trial or other ongoing projects may create uncertainty regarding the company's future prospects.
FAQ
When will Relay Therapeutics report its financial results?
Relay Therapeutics will report its fourth quarter and full year 2025 financial results on February 26, 2026.
What is Relay Therapeutics focused on developing?
Relay Therapeutics is focused on developing precision medicine therapies for cancer and genetic diseases.
What is the significance of zovegalisib in Relay's pipeline?
Zovegalisib is the first pan-mutant selective PI3Kα inhibitor in clinical development for treating specific cancers and genetic diseases.
What kind of trials is zovegalisib currently undergoing?
Zovegalisib is currently in a Phase 3 clinical trial known as ReDiscover-2 for HR+/HER2- metastatic breast cancer.
Where can I find more information about Relay Therapeutics?
More information about Relay Therapeutics can be found on their website at www.relaytx.com or their LinkedIn page.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RLAY Insider Trading Activity
$RLAY insiders have traded $RLAY stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales.
Here’s a breakdown of recent trading of $RLAY stock by insiders over the last 6 months:
- SANJIV PATEL (President and CEO) has made 0 purchases and 2 sales selling 105,241 shares for an estimated $772,084.
- PETER RAHMER (See remarks) has made 0 purchases and 4 sales selling 53,567 shares for an estimated $400,422.
- DONALD A BERGSTROM (President, R&D) has made 0 purchases and 3 sales selling 52,478 shares for an estimated $391,915.
- THOMAS CATINAZZO (Chief Financial Officer) has made 0 purchases and 3 sales selling 37,179 shares for an estimated $277,561.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$RLAY Hedge Fund Activity
We have seen 106 institutional investors add shares of $RLAY stock to their portfolio, and 98 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TANG CAPITAL MANAGEMENT LLC removed 8,068,058 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $68,255,770
- PERCEPTIVE ADVISORS LLC added 1,903,245 shares (+inf%) to their portfolio in Q4 2025, for an estimated $16,101,452
- CASDIN CAPITAL, LLC added 1,662,193 shares (+14.7%) to their portfolio in Q4 2025, for an estimated $14,062,152
- KYNAM CAPITAL MANAGEMENT, LP removed 1,462,755 shares (-50.7%) from their portfolio in Q4 2025, for an estimated $12,374,907
- TCG CROSSOVER MANAGEMENT, LLC added 1,409,835 shares (+77.9%) to their portfolio in Q4 2025, for an estimated $11,927,204
- STATE STREET CORP added 1,360,121 shares (+26.8%) to their portfolio in Q4 2025, for an estimated $11,506,623
- EXODUSPOINT CAPITAL MANAGEMENT, LP added 1,141,880 shares (+inf%) to their portfolio in Q4 2025, for an estimated $9,660,304
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$RLAY Analyst Ratings
Wall Street analysts have issued reports on $RLAY in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 08/26/2025
To track analyst ratings and price targets for $RLAY, check out Quiver Quantitative's $RLAY forecast page.
$RLAY Price Targets
Multiple analysts have issued price targets for $RLAY recently. We have seen 4 analysts offer price targets for $RLAY in the last 6 months, with a median target of $14.0.
Here are some recent targets:
- Matthew Biegler from Oppenheimer set a target price of $14.0 on 01/26/2026
- Eva Fortea Verdejo from Wells Fargo set a target price of $13.0 on 12/12/2025
- Brad Canino from Guggenheim set a target price of $15.0 on 09/04/2025
- Robert Burns from HC Wainwright & Co. set a target price of $14.0 on 08/26/2025
Full Release
CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, will report fourth quarter and full year 2025 financial results and corporate highlights after the U.S. financial markets close on Thursday, February 26, 2026.
About Relay Therapeutics
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. Relay's Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The company’s lead clinical asset, zovegalisib, is the first pan-mutant selective PI3Kα inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Kα-driven vascular anomalies. Relay's pipeline also includes programs for NRAS-driven solid tumors and Fabry disease. For more information, please visit www.relaytx.com or follow us on LinkedIn .
Contact:
Pete Rahmer
[email protected]
Media:
Dan Budwick
1AB
973-271-6085
[email protected]
